UBS: China Life Insurance (02628) new business value growth exceeded expectations. Rating: "Buy"
The line indicates that, as the value of new business has grown strongly this year, China Life holds a more constructive outlook for next year.
UBS released a research report stating that China Life Insurance (02628) saw a 42% increase in new business value in the first nine months, which appears to be better than market expectations; post-tax net profit increased by 61% to 168 billion RMB, in line with earlier profit forecasts. The bank said that with strong growth in new business value this year, China Life has a more constructive outlook for next year. The bank has given the company a "buy" rating with a target price of HK$29.
Related Articles
Anhui Sunhere Pharmaceutical Excipients (300452.SZ) shareholder Shanghai Fosun Pharmaceutical plans to reduce its shareholding by no more than 3%.
DAIDO GROUP (00544) intends to offer a discount of approximately 2.44% on a total of 10 million subscribed shares, raising a net amount of approximately HK$19.72 million.
US Stock Market Move | Concept stocks related to AI applications collectively surged, with Twilio (TWLO.US) rising more than 15% after its earnings release.
Anhui Sunhere Pharmaceutical Excipients (300452.SZ) shareholder Shanghai Fosun Pharmaceutical plans to reduce its shareholding by no more than 3%.
DAIDO GROUP (00544) intends to offer a discount of approximately 2.44% on a total of 10 million subscribed shares, raising a net amount of approximately HK$19.72 million.
US Stock Market Move | Concept stocks related to AI applications collectively surged, with Twilio (TWLO.US) rising more than 15% after its earnings release.
RECOMMEND
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025
Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025
Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025
